STOCK TITAN

Daxor Corporation - DXR STOCK NEWS

Welcome to our dedicated page for Daxor Corporation news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor Corporation stock.

Daxor Corporation Common Stock (DXR) represents a pioneering medical instrumentation and biotechnology company focused on the accurate measurement of blood volume. Daxor develops and markets the BVA-100 (Blood Volume Analyzer), which stands as the first FDA-cleared diagnostic tool capable of providing precise, objective quantification of blood volume status and composition compared to patient-specific norms. This technology is pivotal across a wide range of medical conditions.

The BVA-100 has revolutionized blood volume measurement, a practice that has historically been prone to lengthy and inaccurate testing processes. Traditional methods often took 4 to 8 hours and yielded inconsistent results. In contrast, the BVA-100 can deliver accurate and reliable measurements quickly, enhancing the capabilities of physicians who previously had to rely on less precise tests that measured blood thickness, often leading to misleading outcomes in critical medical situations.

Daxor Corporation, headquartered in New York, is at the forefront of medical technology and innovation. The company's recent achievements include the development of the next generation of Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes. These advancements are not only enhancing the quality of patient care but also strengthening the company's market position.

Financially, Daxor has shown robust growth, with unaudited revenue climbing 229.1% in the first two months of 2024 year-on-year. The company's strong start to 2024 is indicative of its commitment to innovation and excellence. Daxor is also actively engaged in strategic partnerships and investor relations, with Bret Shapiro serving as the Senior Managing Partner at CORE IR, ensuring transparent and effective communication with investors and stakeholders.

In addition to its technological developments, Daxor is also a notable presence in the medical community, participating in significant events such as the Premier Event for Cardiovascular Industry Leaders and Clinicians. The company's research and publications, such as those presented at the American College of Cardiology Scientific Sessions and in the American Heart Journal, underscore its dedication to advancing medical knowledge and practice.

Rhea-AI Summary

Daxor Corporation (NYSE: DXR) announced significant growth in its blood volume diagnostic division, reporting a 26.5% increase in revenue for H1 2021 versus the prior year. CEO Michael Feldschuh highlighted plans for a new point-of-care blood volume analyzer launching in 2022, developed alongside the US DOD. Daxor’s strategy includes strong commercialization, next-gen product development, and improved clinical outcomes, supported by NIH funding for heart failure research. The company aims to expand its market reach significantly, leveraging both internal and external sales forces to enhance performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
-
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) reports a 26.5% revenue increase in its diagnostic division, driven by the commercialization of the BVA-100® Blood Volume Analyzer and new distributor agreements. The company anticipates further growth through a multi-channel distribution model and has opened eight new accounts in 2021. Daxor's next-gen analyzers are set for production in 2022, supported by funding from the U.S. Department of Defense. Despite a 7% decrease in net assets to $14.5 million, the company remains optimistic about its commercialization strategy amidst ongoing COVID-19 challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
none
-
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) recently announced the publication of new data in Critical Care, highlighting the effectiveness of its BVA-100 diagnostic blood test in assessing blood volume alterations in critically ill COVID-19 patients. The research reveals significant capillary damage and blood volume deficits in these patients, emphasizing the need for fluid management. Following this, a multi-center study is underway at prominent hospitals including Wake Forest and NYU Langone Health to further explore these findings, potentially enhancing clinical outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
covid-19
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) has announced a distribution agreement with Concordance Healthcare Solutions, enhancing the availability of its BVA-100® diagnostic blood test across U.S. healthcare facilities. This partnership aims to promote blood volume measurement for improved patient outcomes in conditions like heart failure. Daxor's CEO, Michael Feldschuh, emphasized that this collaboration will boost sales and awareness of their technology. Concordance's Senior Director highlighted that the BVA-100 will help reduce readmissions and healthcare costs, positively impacting patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
-
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) announced an expert analysis titled, "Anemia and Heart Failure: Guidance for Clinicians and Trialists," published in the American College of Cardiology. This analysis highlights the significance of measuring total blood volume in managing anemia among heart failure patients, a condition affecting over 6 million Americans. Daxor's BVA-100 Blood Volume Analyzer is emphasized as a critical tool for accurate blood volume assessment, informing treatment strategies. The company is also developing new testing platforms supported by the U.S. Department of Defense and NIH, expected in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
-
Rhea-AI Summary

Daxor Corporation (NYSE: DXR), a leader in blood volume measurement technology, announces that CEO Michael Feldschuh will present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021, at 4:30 PM ET. He will discuss Daxor's business model, growth strategy, and next-generation technology. The event will be virtual, allowing investors to register for attendance or request one-on-one meetings. The presentation will be available for live streaming and replay on Daxor's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
conferences
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) reported a significant 61% increase in Q1 2021 revenue year-over-year, attributed to the easing of COVID restrictions. The company opened five new customer accounts utilizing its BVA-100 Blood Volume Analyzer and anticipates more acquisitions in Q3 2021, expanding its presence in major medical centers. Daxor is enhancing its sales team to support growth, with expectations to access over 70% of client hospitals by the end of Q2 2021. The company is also advancing next-generation diagnostic technologies that aim to improve patient outcomes and operational efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
-
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) announces the start of a multi-center clinical trial with Veterans Affairs Medical Centers to assess Blood Volume Analysis (BVA) for managing acute decompensated heart failure (ADHF) using the BVA-100 blood test. The NIH intends to fund this landmark study, which aims to enhance treatment outcomes for over 6 million heart failure patients in the U.S. Previous data indicates that BVA-100 guided care could reduce patient mortality by over 82% and readmissions by 56%. The study is vital for validating Daxor's clinical guidance system and advancing heart failure management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) announced new findings regarding the BVA-100 blood test's effectiveness in managing Postural Tachycardia Syndrome (POTS). Published in the Journal of the American College of Cardiology, the study demonstrated that a high sodium diet increased plasma volume and reduced heart rate in POTS patients. The BVA-100 test provides accurate blood volume measurements, affirming its role as a crucial tool for treatment optimization in POTS. Daxor continues to position itself as a leader in blood volume measurement technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) announces that President and CEO Michael Feldschuh will participate in the Benzinga Biotech Small Cap Conference on March 24-25, 2021. His presentation on March 24 at 12:30 PM EDT will cover the company's business model, growth strategy, and advancements in blood volume measurement technology, including updates on research and contracts with the US Department of Defense. Investors can register to view the presentation and request one-on-one meetings with Feldschuh.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of Daxor Corporation (DXR)?

The current stock price of Daxor Corporation (DXR) is $8.2999 as of December 23, 2024.

What is the market cap of Daxor Corporation (DXR)?

The market cap of Daxor Corporation (DXR) is approximately 40.8M.

What does Daxor Corporation specialize in?

Daxor Corporation specializes in medical instrumentation and biotechnology, with a focus on precise blood volume measurement using their BVA-100 system.

What is the BVA-100?

The BVA-100 is a Blood Volume Analyzer, the first FDA-cleared diagnostic tool that provides accurate quantification of blood volume and composition.

How has the BVA-100 improved blood volume measurement?

The BVA-100 provides quick, accurate, and reliable blood volume measurements, overcoming the lengthy and inaccurate traditional methods.

What are some recent achievements of Daxor Corporation?

Recent achievements include the development of the next generation Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes.

How has Daxor performed financially in early 2024?

Daxor reported a strong start to 2024 with unaudited revenue climbing 229.1% in the first two months year-on-year.

Who is the Investor Relations Contact at Daxor Corporation?

Bret Shapiro, the Senior Managing Partner at CORE IR, is the Investor Relations Contact for Daxor Corporation.

What kind of medical events does Daxor participate in?

Daxor participates in significant medical events like the Premier Event for Cardiovascular Industry Leaders and Clinicians.

Where has Daxor Corporation published its research findings?

Daxor has presented data at the American College of Cardiology Scientific Sessions and published research in the American Heart Journal.

What is the significance of the BVA-100 in medical practice?

The BVA-100 provides physicians with accurate blood volume data, improving diagnosis and treatment in various medical and surgical situations.

Where is Daxor Corporation headquartered?

Daxor Corporation is headquartered in New York.

Daxor Corporation

NYSE:DXR

DXR Rankings

DXR Stock Data

40.78M
2.03M
56.52%
1.94%
0.13%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW YORK